NCT00612144View on ClinicalTrials.gov

Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM

PHASE4CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Glimepiride/metformin fixed combination

"Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"

DRUG

Metformin HCl

"Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG"

Trial Locations (1)

Unknown

Handok Pharmaceuticals, Co., LTD, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
lead

Handok Inc.

INDUSTRY

NCT00612144 - Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM | Biotech Hunter | Biotech Hunter